Filing Details

Accession Number:
0001209191-21-055206
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-08 18:42:53
Reporting Period:
2021-09-03
Accepted Time:
2021-09-08 18:42:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178879 Amicus Therapeutics Inc. FOLD Pharmaceutical Preparations (2834) 200422823
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1743122 Samantha Prout C/O Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia PA 19104
Principal Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-09-03 1,980 $10.04 85,150 No 4 M Direct
Common Stock Acquisiton 2021-09-03 2,945 $9.55 88,095 No 4 M Direct
Common Stock Disposition 2021-09-03 4,925 $12.01 83,170 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2021-09-03 1,980 $0.00 1,980 $10.04
Common Stock Stock Options (right to buy) Disposition 2021-09-03 2,945 $0.00 2,945 $9.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,168 2029-01-02 No 4 M Direct
12,182 2030-01-02 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.0650 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. As of September 3, 2021, 1,980 options were fully vested and exercisable and 3,168 remained unvested from this grant.
  4. As of September 3, 2021, 6,301 options were fully vested and exercisable and 8,826 remained unvested from this grant.